Chemistry Department, Institute for Drug Discovery, Purdue University, West Lafayette, IN 47907, USA.
Purdue Institute for Inflammation, Immunology, and Infectious Diseases, West Lafayette, IN 47907, USA.
Molecules. 2019 Nov 19;24(22):4192. doi: 10.3390/molecules24224192.
Ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1) was identified several decades ago as a type II transmembrane glycoprotein with nucleotide pyrophosphatase and phosphodiesterase enzymatic activities, critical for purinergic signaling. Recently, ENPP1 has emerged as a critical phosphodiesterase that degrades the stimulator of interferon genes (STING) ligand, cyclic GMP-AMP (cGAMP). cGAMP or analogs thereof have emerged as potent immunostimulatory agents, which have potential applications in immunotherapy. This emerging role of ENPP1 has placed this "old" enzyme at the frontier of immunotherapy. This review highlights the roles played by ENPP1, the mechanism of cGAMP hydrolysis by ENPP1, and small molecule inhibitors of ENPP1 with potential applications in diverse disease states, including cancer.
核苷酸焦磷酸酶/磷酸二酯酶 I(ENPP1)几十年前被鉴定为一种 II 型跨膜糖蛋白,具有核苷酸焦磷酸酶和磷酸二酯酶的酶活性,对嘌呤能信号至关重要。最近,ENPP1 作为一种关键的磷酸二酯酶出现,可降解干扰素基因刺激物(STING)配体,环鸟苷酸-腺苷酸(cGAMP)。cGAMP 或其类似物已成为有效的免疫刺激剂,在免疫疗法中有潜在的应用。ENPP1 的这种新作用使这种“旧”酶处于免疫疗法的前沿。本综述强调了 ENPP1 的作用、ENPP1 水解 cGAMP 的机制以及在包括癌症在内的多种疾病状态中具有潜在应用的 ENPP1 小分子抑制剂。